A Fortune 500 company, in conjunction with IBM Watson Health, conducted an economic evaluation to test whether our flagship digital therapeutic for insomnia, Sleepio, would lower health care costs for their employees.
Individuals who used Sleepio had 28% lower annualized total healthcare costs compared to those who did not use Sleepio — demonstrating $1,677 lower health care costs per employee that used Sleepio.
A peek inside:
Here’s our latest
How a Fortune 50 retailer lowered health care costs by nearly 20% with Sleepio for insomnia
The new health economic research report by a Johns Hopkins professor shows use of a digital therapeutic lowers overall healthcare…
Using Clinical Evidence to Evaluate Digital Therapeutics for Mental Health
Benefits leaders are turning to digital therapeutics to address employee mental health, but many questions remain. How can you distinguish…
The impact of good mental health in manufacturing
Our report gives you all the evidence you need to make the case for investing in employee mental health through…